Immune impairment in patients with terminal cancers: Influence of cancer treatments and cytomegalovirus infection

I. Hsuan Chen, Yuen Liang Lai, Chien Liang Wu, Yi Fang Chang, Chen Chung Chu, I. Fang Tsai, Fang Ju Sun, Yen Ta Lu

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Although immunodeficiency is usually considered a prerequisite of oncogenesis, a detailed immune profile in cancer has not yet been described. Without such profiling, it is not surprising that there is a vast discrepancy in the responses of cancer patients to immunotherapy. Our results show that the integrity of the immune system deteriorates with cancer progression by displaying a trend toward decreasing levels of functional T cells, including CD4, naïve, and central memory T cells, and an expansion of hyporesponsive populations such as CD28- and CMV-specific T cells. One hundred and one patients constitute the study group for the observational study reported in this paper. Forty-eight patients with newly diagnosed stages III and IV and 53 patients with extensively treated stage IV disease. The costimulatory molecules CD27 and CD28 were downregulated in all patients. Among the proinflammatory cytokines (IL-6, TNF-α, IFN-γ), only IL-6 differed significantly among the groups, increasing as the cancer stage progressed. Plasma IL-7 did not differ among the participants. The relative deficits of naïve T cells in cancer patients may be associated with the downregulation of IL-7Rα expression rather than changes in the circulating levels of IL-7. The downregulation of IL-7Rα expression was shown to be associated with increased levels of intracellular CMV. The present study suggests that the immune impairment in patients with cancer is associated with multiple factors, such as the stage of cancer, consequence of CMV infection and impact of treatment.

Original languageEnglish
Pages (from-to)323-334
Number of pages12
JournalCancer Immunology and Immunotherapy
Volume59
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Cytomegalovirus Infections
Neoplasms
T-Lymphocytes
Interleukin-7
Down-Regulation
Therapeutics
Interleukin-6
Immunotherapy
Observational Studies
Immune System
Carcinogenesis
Cytokines
Infection
Population

Keywords

  • Cancer
  • Chemotherapy
  • Cytokines
  • Cytomegalovirus
  • Immune profile

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Immune impairment in patients with terminal cancers : Influence of cancer treatments and cytomegalovirus infection. / Chen, I. Hsuan; Lai, Yuen Liang; Wu, Chien Liang; Chang, Yi Fang; Chu, Chen Chung; Tsai, I. Fang; Sun, Fang Ju; Lu, Yen Ta.

In: Cancer Immunology and Immunotherapy, Vol. 59, No. 2, 02.2010, p. 323-334.

Research output: Contribution to journalArticle

Chen, I. Hsuan ; Lai, Yuen Liang ; Wu, Chien Liang ; Chang, Yi Fang ; Chu, Chen Chung ; Tsai, I. Fang ; Sun, Fang Ju ; Lu, Yen Ta. / Immune impairment in patients with terminal cancers : Influence of cancer treatments and cytomegalovirus infection. In: Cancer Immunology and Immunotherapy. 2010 ; Vol. 59, No. 2. pp. 323-334.
@article{407e4bfb236648259526ec95f3bb320a,
title = "Immune impairment in patients with terminal cancers: Influence of cancer treatments and cytomegalovirus infection",
abstract = "Although immunodeficiency is usually considered a prerequisite of oncogenesis, a detailed immune profile in cancer has not yet been described. Without such profiling, it is not surprising that there is a vast discrepancy in the responses of cancer patients to immunotherapy. Our results show that the integrity of the immune system deteriorates with cancer progression by displaying a trend toward decreasing levels of functional T cells, including CD4, na{\"i}ve, and central memory T cells, and an expansion of hyporesponsive populations such as CD28- and CMV-specific T cells. One hundred and one patients constitute the study group for the observational study reported in this paper. Forty-eight patients with newly diagnosed stages III and IV and 53 patients with extensively treated stage IV disease. The costimulatory molecules CD27 and CD28 were downregulated in all patients. Among the proinflammatory cytokines (IL-6, TNF-α, IFN-γ), only IL-6 differed significantly among the groups, increasing as the cancer stage progressed. Plasma IL-7 did not differ among the participants. The relative deficits of na{\"i}ve T cells in cancer patients may be associated with the downregulation of IL-7Rα expression rather than changes in the circulating levels of IL-7. The downregulation of IL-7Rα expression was shown to be associated with increased levels of intracellular CMV. The present study suggests that the immune impairment in patients with cancer is associated with multiple factors, such as the stage of cancer, consequence of CMV infection and impact of treatment.",
keywords = "Cancer, Chemotherapy, Cytokines, Cytomegalovirus, Immune profile",
author = "Chen, {I. Hsuan} and Lai, {Yuen Liang} and Wu, {Chien Liang} and Chang, {Yi Fang} and Chu, {Chen Chung} and Tsai, {I. Fang} and Sun, {Fang Ju} and Lu, {Yen Ta}",
year = "2010",
month = "2",
doi = "10.1007/s00262-009-0753-0",
language = "English",
volume = "59",
pages = "323--334",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - Immune impairment in patients with terminal cancers

T2 - Influence of cancer treatments and cytomegalovirus infection

AU - Chen, I. Hsuan

AU - Lai, Yuen Liang

AU - Wu, Chien Liang

AU - Chang, Yi Fang

AU - Chu, Chen Chung

AU - Tsai, I. Fang

AU - Sun, Fang Ju

AU - Lu, Yen Ta

PY - 2010/2

Y1 - 2010/2

N2 - Although immunodeficiency is usually considered a prerequisite of oncogenesis, a detailed immune profile in cancer has not yet been described. Without such profiling, it is not surprising that there is a vast discrepancy in the responses of cancer patients to immunotherapy. Our results show that the integrity of the immune system deteriorates with cancer progression by displaying a trend toward decreasing levels of functional T cells, including CD4, naïve, and central memory T cells, and an expansion of hyporesponsive populations such as CD28- and CMV-specific T cells. One hundred and one patients constitute the study group for the observational study reported in this paper. Forty-eight patients with newly diagnosed stages III and IV and 53 patients with extensively treated stage IV disease. The costimulatory molecules CD27 and CD28 were downregulated in all patients. Among the proinflammatory cytokines (IL-6, TNF-α, IFN-γ), only IL-6 differed significantly among the groups, increasing as the cancer stage progressed. Plasma IL-7 did not differ among the participants. The relative deficits of naïve T cells in cancer patients may be associated with the downregulation of IL-7Rα expression rather than changes in the circulating levels of IL-7. The downregulation of IL-7Rα expression was shown to be associated with increased levels of intracellular CMV. The present study suggests that the immune impairment in patients with cancer is associated with multiple factors, such as the stage of cancer, consequence of CMV infection and impact of treatment.

AB - Although immunodeficiency is usually considered a prerequisite of oncogenesis, a detailed immune profile in cancer has not yet been described. Without such profiling, it is not surprising that there is a vast discrepancy in the responses of cancer patients to immunotherapy. Our results show that the integrity of the immune system deteriorates with cancer progression by displaying a trend toward decreasing levels of functional T cells, including CD4, naïve, and central memory T cells, and an expansion of hyporesponsive populations such as CD28- and CMV-specific T cells. One hundred and one patients constitute the study group for the observational study reported in this paper. Forty-eight patients with newly diagnosed stages III and IV and 53 patients with extensively treated stage IV disease. The costimulatory molecules CD27 and CD28 were downregulated in all patients. Among the proinflammatory cytokines (IL-6, TNF-α, IFN-γ), only IL-6 differed significantly among the groups, increasing as the cancer stage progressed. Plasma IL-7 did not differ among the participants. The relative deficits of naïve T cells in cancer patients may be associated with the downregulation of IL-7Rα expression rather than changes in the circulating levels of IL-7. The downregulation of IL-7Rα expression was shown to be associated with increased levels of intracellular CMV. The present study suggests that the immune impairment in patients with cancer is associated with multiple factors, such as the stage of cancer, consequence of CMV infection and impact of treatment.

KW - Cancer

KW - Chemotherapy

KW - Cytokines

KW - Cytomegalovirus

KW - Immune profile

UR - http://www.scopus.com/inward/record.url?scp=71849084149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849084149&partnerID=8YFLogxK

U2 - 10.1007/s00262-009-0753-0

DO - 10.1007/s00262-009-0753-0

M3 - Article

C2 - 19685052

AN - SCOPUS:71849084149

VL - 59

SP - 323

EP - 334

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -